News | February 10, 2024
Zydus Lifesciences Q3 FY24 PAT up 26.8%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
Trinity has availed credit facility from Investec for Business for their working capital requirements of Rs. 31.5 crore
His most recent stint was with Danone India as its Managing Director
10+ emerging markets, Japan & ANZ transition in final phase
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
European operations' revenue grew 58.4% to Rs 599.7 crore
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Subscribe To Our Newsletter & Stay Updated
